Development and validation of case-finding algorithms to identify prosthetic joint infections after total knee arthroplasty in Veterans Health Administration data.

epidemiologic methods outcomes pharmacoepidemiology prosthetic joint infection total knee arthroplasty validation studies veteran

Journal

Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369

Informations de publication

Date de publication:
09 2021
Historique:
revised: 17 06 2021
received: 20 04 2021
accepted: 21 06 2021
pubmed: 26 6 2021
medline: 15 12 2021
entrez: 25 6 2021
Statut: ppublish

Résumé

To determine the positive predictive values (PPVs) of ICD-9, ICD-10, and current procedural terminology (CPT)-based diagnostic coding algorithms to identify prosthetic joint infection (PJI) following knee arthroplasty (TKA) within the United States Veterans Health Administration. We identified patients with: (1) hospital discharge ICD-9 or ICD-10 diagnosis of PJI, (2) ICD-9, ICD-10, or CPT procedure code for TKA prior to PJI diagnosis, (3) CPT code for knee X-ray within ±90 days of the PJI diagnosis, and (4) at least 1 CPT code for arthrocentesis, arthrotomy, blood culture, or microbiologic procedure within ±90 days of the PJI diagnosis date. Separate samples of patients identified with the ICD-9 and ICD-10-based PJI diagnoses were obtained, stratified by TKA procedure volume at each medical center. Medical records of sampled patients were reviewed by infectious disease clinicians to adjudicate PJI events. The PPV (95% confidence interval [CI]) for the ICD-9 and ICD-10 PJI algorithms were calculated. Among a sample of 80 patients meeting the ICD-9 PJI algorithm, 60 (PPV 75.0%, [CI 64.1%-84.0%]) had confirmed PJI. Among 80 patients who met the ICD-10 PJI algorithm, 68 (PPV 85.0%, [CI 75.3%-92.0%]) had a confirmed diagnosis. An algorithm consisting of an ICD-9 or ICD-10 PJI diagnosis following a TKA code combined with CPT codes for a knee X-ray and either a relevant surgical procedure or microbiologic culture yielded a PPV of 75.0% (ICD-9) and 85.0% (ICD-10), for confirmed PJI events and could be considered for use in future pharmacoepidemiologic studies.

Identifiants

pubmed: 34170057
doi: 10.1002/pds.5316
pmc: PMC8343957
mid: NIHMS1721677
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1184-1191

Subventions

Organisme : NIAAA NIH HHS
ID : P01 AA029545
Pays : United States
Organisme : NIAAA NIH HHS
ID : U24 AA022001
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NIAAA NIH HHS
ID : U10 AA013566
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA020790
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI055435
Pays : United States
Organisme : NIAAA NIH HHS
ID : U24 AA020794
Pays : United States

Informations de copyright

© 2021 John Wiley & Sons Ltd.

Références

PLoS Med. 2020 Sep 22;17(9):e1003379
pubmed: 32960880
Health Serv Res. 2008 Aug;43(4):1424-41
pubmed: 18756617
J Arthroplasty. 2015 Sep;30(9):1492-7
pubmed: 25865815
Infect Control Hosp Epidemiol. 2021 Mar;42(3):325-330
pubmed: 32993826
BMJ. 1994 Jul 9;309(6947):102
pubmed: 8038641
J Arthroplasty. 2012 Sep;27(8 Suppl):61-5.e1
pubmed: 22554729
PLoS One. 2016 Mar 03;11(3):e0150866
pubmed: 26938768
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Bone Joint J. 2016 Mar;98-B(3):320-5
pubmed: 26920956
JAMIA Open. 2019 Jun 11;2(3):312-316
pubmed: 32537568
J Arthroplasty. 2010 Aug;25(5):766-71.e1
pubmed: 19679438
Int Orthop. 2020 Jul;44(7):1255-1261
pubmed: 32449042
Clin Orthop Relat Res. 2011 Nov;469(11):2992-4
pubmed: 21938532
J Bone Joint Surg Am. 2011 Jul 20;93(14):1355-7
pubmed: 21792503
Osteoarthritis Cartilage. 2010 Dec;18(12):1639-42
pubmed: 20950694
J Arthroplasty. 2014 Jul;29(7):1331
pubmed: 24768547

Auteurs

Erica J Weinstein (EJ)

Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Alisa Stephens-Shields (A)

Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Bogadi Loabile (B)

Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Tiffany Yuh (T)

Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Randi Silibovsky (R)

Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Charles L Nelson (CL)

Department of Orthopedic Surgery, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Judith A O'Donnell (JA)

Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Evelyn Hsieh (E)

VA Connecticut Health System, West Haven, Connecticut, USA.
Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Section of Rheumatology, Allergy and Immunology, Yale University School of Medicine, New Haven, Connecticut, USA.

Jennifer S Hanberg (JS)

VA Connecticut Health System, West Haven, Connecticut, USA.
Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

Kathleen M Akgün (KM)

VA Connecticut Health System, West Haven, Connecticut, USA.
Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

Janet P Tate (JP)

VA Connecticut Health System, West Haven, Connecticut, USA.
Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

Vincent Lo Re (V)

Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH